The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing ...

XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug applica ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

This is an important behavioral, pharmacological intervention study of the effects of the catecholamine reuptake inhibitor methylphenidate (MPH) on value-based decision-making using a combination of ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Mineralys has been on the radar for some biotech investors. Read more about MLYS' hypertension treatment, upcoming trial ...

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

A new perspective on dysregulation challenges the role of serotonin and puts the focus on the body and organs.

A cortical tri-culture model advances the validation process in neurodegenerative drug discovery, offering new possibilities ...

Common medicines used to treat conditions including heartburn, reflux, indigestion and stomach ulcers may be the subject of a ...